Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERC-002 in COVID-19 Pneumonia and ARDS
NCT04412057Phase 2Completed
- Sponsor
- Avalo Therapeutics
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of quisovalimab in COVID-19 pneumonia, acute respiratory distress syndrome (ARDS), sponsored by Avalo Therapeutics. Started Jul 2020; status: completed.
02
Drugs
quisovalimab
03
Conditions
COVID-19 pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04412057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04412057.